JPRN-jRCT2080220279未知2 期
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline K.K.0 个研究点开始时间: 2006年7月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •- 18 Years and above
- •- ErbB2(HER2)overexpressing breast cancer.
- •- Brain lesion(s) which are progressing.
- •- Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR) and/or Stereotactic Radiosurgery (SRS).
- •- Prior treatment with Trastuzumab (Herceptin), either alone or in combination with chemotherapy.
- •- Cardiac ejection fraction (LVEF) within the institutional range of normal as measured by Echocardiogram.
- •- Adequate liver, kidney and bone marrow function.
- •- Pregnant or lactating females.
- •- Conditions that would effect the absorption of an oral drug.
- •- History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents.
- •- Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel.
排除标准
- 未提供
研究者
相似试验
招募中
不适用
Brain Metastases in Breast Cancer Network Germany (BMBC)DRKS00011830Principal InvestigatorKlinik und Poliklinik für Gynäkologie Universitätsklinikum Hamburg-Eppendorf4,000
撤回
2 期
Eribulin in Brain Metastases From HER2-negative Breast CancerMetastatic Breast CancerNCT03637868Institut Paoli-Calmettes
已完成
1 期
Prophylactic Cranial Irradiation in Patients With HER-2-Positive Metastatic Breast CancerBreast CancerNCT00916877Alberta Health services110
已完成
不适用
Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2Breast NeoplasmsNCT00071383National Institute of Neurological Disorders and Stroke (NINDS)78
终止
1 期
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast CancerBrain MetastasesHER2-positive Breast CancerNCT05553522Baptist Health South Florida1